ozanimod

Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Novartis' MS patent win also a win for Celgene's impending MS drug: analyst
Medical Marketing and Media
Celgene
Novartis
ozanimod
Gilenya
MS
multiple sclerosis
patents
Flag link:
Pharma's 2 Biggest Setbacks in 2018
Pharma's 2 Biggest Setbacks in 2018
Motley Fool
AbbVie
Celgene
Rova-T
ozanimod
Flag link:
Celgene executive blames Receptos for ozanimod filing fail
Celgene executive blames Receptos for ozanimod filing fail
Fierce Biotech
Celgene
Receptos
ozanimod
Flag link:
Celgene's timeline for refiling ozanimod gets mixed reviews
Celgene's timeline for refiling ozanimod gets mixed reviews
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
FDA
Flag link:
A metabolite will make or break Celgene's ozanimod
A metabolite will make or break Celgene's ozanimod
Biopharma Dive
Celgene
ozanimod
MS
multiple sclerosis
metabolite
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
CP Wire
Celgene
ozanimod
relapsing multiple sclerosis
MS
Flag link:
Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials
Celgene Corporation
multiple sclerosis
ozanimod
Flag link:
Arena Pharmaceuticals Takes Aim at Celgene
Arena Pharmaceuticals Takes Aim at Celgene
Motley Fool
Arena Pharmaceuticals
Celgene
etrasimod
ozanimod
ulcerative colitis
Flag link:

Pages